Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Epidermal growth factor receptor (EGFR) is overexpressed in various human cancers, making it a promising therapeutic target.
• The therapeutic potential of T cells engineered to target EGFR remains to be fully understood.

Purpose of the Study:

• To investigate the anticancer potential of anti-EGFR single-chain variable fragment (scFv) based cell-targeted therapy.
• To construct and evaluate chimeric antigen receptor (CAR) T cells against EGFR-overexpressing tumors.

Main Methods:

• Identification of a high-affinity anti-EGFR scFv using ribosome display.
• Construction and expression of an EGFR-specific CAR on T lymphocytes.
• In vitro and in vivo evaluation of CAR-modified T cell antitumor efficacy and safety.

Main Results:

• CAR-modified T cells exhibited significant antitumor activity against EGFR-overexpressing tumor cells in vitro and in vivo.
• Safety evaluation indicated no or minimal acute systemic toxicity associated with the CAR-modified lymphocytes.

Conclusions:

• Genetically engineered T cells targeting EGFR show promising preclinical efficacy and safety.
• This study provides an experimental basis for the clinical application of EGFR-targeted CAR T cell therapy.